NDAC meetings rescheduled
This article was originally published in The Tan Sheet
Executive Summary
Nonprescription Drugs Advisory Committee tentative meeting dates have been rescheduled for June 12-13 and Sept. 16-17. Dietary Supplements Subcommittee tentative meeting dates still slated for March 27-28 and Sept. 22-23, as reported in 1"The Tan Sheet" Dec. 23, 2002, In Brief...
You may also be interested in...
FDA supplement subcommittee
Meeting scheduled for March 25 will evaluate "recognized scientific principles that would facilitate reaching a conclusion as to whether a particular substance is a 'metabolite' of another substance that is a 'dietary ingredient' defined in the [FD&C Act] and, therefore, is itself a dietary ingredient," according to March 5 Federal Register notice. FDA says the act currently "is ambiguous...as to what substances are, or are not, metabolites of other substances," which makes it "often difficult to determine whether a particular substance...can be marketed as [a] dietary supplement." Meeting will be held at Holiday Inn, 10,000 Baltimore Ave., College Park, Md. Dietary Supplement Subcommittee of the Food Advisory Committee will not meet March 27-28, as reported in 1"The Tan Sheet" Feb. 10, 2003, In Brief...
FDA advisory committees
Nonprescription Drugs Advisory Committee slated to meet March 6-7, June 13-14 and Sept. 16-17, according to 1tentative 2003 advisory committee schedule published in Dec. 19 Federal Register. NDAC considered Rx-to-OTC switch applications for Schering-Plough's Claritin (loratadine) and AstraZeneca/Procter & Gamble's Prilosec (omeprazole), and discussed labeling and marketing for acetaminophen, aspirin and NSAIDs in 2002. CFSAN's Dietary Supplements Subcommittee of the Food Advisory Committee is slated to meet March 27-28 and Sept. 22-23, while the parent committee is scheduled to convene Feb. 24-26 and Aug. 18-20...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.